| Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma N Korde, M Roschewski, A Zingone, M Kwok, EE Manasanch, M Bhutani, ... JAMA oncology 1 (6), 746-754, 2015 | 329 | 2015 |
| A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma N Korde, M Carlsten, MJ Lee, A Minter, E Tan, M Kwok, E Manasanch, ... Haematologica 99 (6), e81, 2014 | 134 | 2014 |
| Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases PR Tembhare, CM Yuan, D Venzon, R Braylan, N Korde, E Manasanch, ... Leukemia research 38 (3), 371-376, 2014 | 102 | 2014 |
| Bendamustine: something old, something new N Tageja, J Nagi Cancer chemotherapy and pharmacology 66, 413-423, 2010 | 93 | 2010 |
| Phase II clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) induces high rates of MRD negativity in … N Korde, A Zingone, ML Kwok, EE Manasanch, M Bhutani, N Tageja, ... Blood 122 (21), 538, 2013 | 67 | 2013 |
| Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines N Tageja, H Groninger Postgraduate medical journal 92 (1083), 34-40, 2016 | 48 | 2016 |
| Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma S Mailankody, D Kazandjian, N Korde, M Roschewski, E Manasanch, ... Blood advances 1 (22), 1911-1918, 2017 | 47 | 2017 |
| Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma S Sethi, N Tageja, M Dave, A Badheka, S Revankar, H Arabi, J Singh The American journal of the medical sciences 338 (6), 522-524, 2009 | 44 | 2009 |
| Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity. JA Zonder, V Sanchorawala, RM Snyder, J Matous, H Terebelo, ... Blood 114 (22), 746, 2009 | 44 | 2009 |
| Lenalidomide-current understanding of mechanistic properties N Tageja Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2011 | 42 | 2011 |
| Squamous cell cancer of the anal canal in HIV-infected patients receiving highly active antiretroviral therapy: a single institution experience N Hammad, LK Heilbrun, S Gupta, N Tageja, PA Philip, AF Shields, ... American journal of clinical oncology 34 (2), 135-139, 2011 | 38 | 2011 |
| Bendamustine: safety and efficacy in the management of indolent non-Hodgkins lymphoma N Tageja Clinical Medicine Insights: Oncology 5, CMO. S6085, 2011 | 34 | 2011 |
| The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma EE Manasanch, N Korde, A Zingone, N Tageja, C Fernandez de Larrea, ... Leukemia & lymphoma 55 (8), 1707-1714, 2014 | 33 | 2014 |
| Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method EE Manasanch, DA Salem, CM Yuan, N Tageja, M Bhutani, M Kwok, ... Leukemia & lymphoma 56 (5), 1416-1424, 2015 | 31 | 2015 |
| Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma D Bhutani, J Zonder, J Valent, N Tageja, L Ayash, A Deol, Z Al-Kadhimi, ... Supportive Care in Cancer 21, 2437-2442, 2013 | 29 | 2013 |
| MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström’s Macroglobulinemia O Landgren, N Tageja Leukemia 28 (9), 1799-1803, 2014 | 28 | 2014 |
| Bridging the translation gap–new hopes, new challenges N Tageja Fundamental & clinical pharmacology 25 (2), 163-171, 2011 | 26 | 2011 |
| Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging M Bhutani, B Turkbey, E Tan, N Korde, M Kwok, EE Manasanch, N Tageja, ... Leukemia & lymphoma 57 (5), 1114-1121, 2016 | 25 | 2016 |
| A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma … MH Abidi, R Agarwal, N Tageja, L Ayash, A Deol, Z Al-Kadhimi, J Abrams, ... Biology of Blood and Marrow Transplantation 19 (1), 56-61, 2013 | 25 | 2013 |
| Myonecrosis in sickle cell anemia—overlooked and underdiagnosed N Tageja, M Racovan, J Valent, J Zonder Case reports in medicine 2010, 2010 | 24 | 2010 |
